Recorded fact · drug.label_indication
drug.label_indication for empagliflozin-linagliptin|type-2-diabetes
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 1db9c09c resolves to.
The record
| Fact id | 1db9c09cb76960c4df1a73ef |
|---|---|
| Entity | drug: empagliflozin-linagliptin|type-2-diabetes |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260120 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .
Shown with dashes as hyphens. SHA-256 of the exact stored quote: c670f748980d7eb3df89adb8b3abaa8333df9df17a4eb7a486d0b634a8e16920.
The value
{
"ingredient": "Empagliflozin/Linagliptin",
"conditionId": "type-2-diabetes",
"conditionName": "Type 2 diabetes",
"matchedAlias": "type 2 diabetes",
"context": "indication",
"brand": "Glyxambi",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "ddbab689-f76c-488c-9613-4168d41dd730",
"labelEffectiveTime": "20260120",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 22419777c66deb4864f3e962d819daebde3219ef2befc9a173a3ca761594056b.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.